The current study demonstrated that there are unique molecular features in a large consecutive Chinese colorectal cancer cohort undergoing universal screening for Lynch Syndrome, characterized by high prevalence and infrequent BRAF V600E mutation. These results verified the ethnic diversity among lynch syndrome. Patients older than 65 years who do not meet the revised Bethesda guidelines have a low risk of lynch syndrome, suggesting germline sequencing might not be necessary in this population.
Introduction
Lynch syndrome (LS), is the most common hereditary colorectal cancer (CRC) syndrome, accounting for 2%-4% of all CRC cases. [1] [2] [3] [4] LS is caused by germline mutations in one of four mismatch repair (MMR) genes (MLH1, MSH2, MSH6 and PMS2) 5 , or deletions in the 5' area of EPCAM which result in hypermethylation of the MSH2 promoter and subsequent MSH2 silencing. 6, 7 Patients with LS are susceptible to various cancers and often at a young age. [8] [9] [10] [11] Both the US National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment (Colorectal) and the National Institute for Health and Care Excellence (NICE) in the UK now recommend universal screening of all CRC to improve the identification of individuals with LS. 12, 13 The prevalence of LS varies significantly in different populations, suggesting that ethnic diversity might play an important role in the disease. To our knowledge, screening for LS has been mainly performed in western populations and data regarding Chinese patients is scarce.
Because of China's large population, delineation of the prevalence and genotype of LS in Chinese patients would help to understand the ethnic diversity of LS.
Since the universal screening strategy has been gradually adopted worldwide, it is interesting to explore the prevalence of LS in patients with MMR protein deficiency (dMMR) in different age of onset. In this way, we could identify the patients with high risk of LS for germline sequencing and optimize the screening strategy.
Herein, we conducted universal screening for LS in a consecutive large cohort with newly diagnosed CRC, using immunohistochemical (IHC) staining for MMR proteins, followed by BRAF V600E testing in cases with absence of MLH1, and then multigene panel testing on germline DNA in all cases with dMMR and no BRAF V600E mutation.
We investigated the prevalence of dMMR and LS in these unselected CRC patients and further evaluated the associations between age of onset and prevalence of LS in patients with dMMR tumors. Finally, the efficiency of a selective strategy consisting of universal tumor MMR testing and specific clinical criteria was tested.
Materials and Methods

Patients and Screening strategy
Between November 2011 and December 2015, 3330 consecutive patients who had surgical resection for newly diagnosed colorectal adenocarcinoma at the Sun Yat-sen University Cancer Center, China were enrolled in this study. Eighty patients with a clinical diagnosis of polyposis or with insufficient tumor tissue for IHC were excluded. The protocol was approved by the clinical research ethics committee of the Cancer Center. All patients provided written informed consent to participate in the study. All data in our study have been recorded at Sun Yat-sen University Cancer Center for future reference (number RDDA2018000384).
The screening strategy is detailed in Figure 1 . In brief, IHC for four MMR proteins was performed universally to identify patients with dMMR as evidenced by the absence of one or more of the MMR proteins. If the MLH1 protein was absent, BRAF V600E mutation testing was performed in the tumor to exclude cases with suspected MLH1 gene promoter methylation. Patients with dMMR and no BRAF V600E mutation were referred for genetic counseling and identified as candidates for germline sequencing.
IHC and BRAF V600E mutation testing
All specimens were prepared as 4μm After filtering the low quality reads, clean sequencing data were aligned to reference (UCSC, hg19) using BWA0.6.2 (Burrow-wheeler Aligner), marked for duplication by Picard (V1.98) and re-aligned by GATK (v3.5, Broad Institute, Cambridge, MA, USA). After that, the final mapping file (BAM format) was used to detect the SNP/InDel by GATK software. In-house developed software was used to detect gene exonic deletion/duplication mutation. SNP/InDel mutations with less than 25% mutational frequency were filtered. Mutations were annotated based on RefSeq GTF file. The SNP frequency was annotated by Dbsnp141, ExAC, 1000 genomes project and so on. The pathogenicity of mutations was classified according to American This article is protected by copyright. All rights reserved.
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College of Medical Genetics and Genomics (ACMG) recommendations. 14 All the pathogenic and likely pathogenic SNP/InDel mutations were confirmed by Sanger sequencing. All the copy number variations (CNV) were validated by qPCR method. Domain region in the MMR genes was defined by Pfam database. We took the known pathogenic missense mutations from our in-house database as positive control and the in-house benign missense database and mutations with >0.01 allele frequency in human published databases served as a negative control. If one domain region only contains pathogenic mutation, it was defined as a highly conserved functional domain.
Those mutations located in highly conserved regions were considered as moderate evidence for pathogenic nature. Any missense mutations of uncertain significance were re-evaluated for their location, in silico prediction results, phenotype, family history, and also checked against the International Society of Gastrointestinal Hereditary Tumors (InSiGHT) reference Leiden Open Variation Database (LOVD) at http://www.insight-database.org/genes in order to further assess pathogenicity.
Statistical Analysis
Demographic data were summarized as mean (± standard deviation) or frequency (%).
Sensitivity, Specificity, positive predictive value, negative predictive value and diagnostic yield of screening strategies were calculated. SPSS statistical software, version 17(Chicago, USA: SPSS Inc.) were used to perform the analyses.
Results
Prescreening for LS
A total of 3250 patients were eligible for analysis. Men accounted for 59.8% (n = 
Outcomes of Germline sequencing
Among the 256 patients with dMMR tumors who underwent germline genetic testing, 99 pathogenic or likely pathogenic mutations were discovered in 93 patients (eTable 1 in the Supplement). Therefore, the prevalence of Lynch syndrome is 2.9% (93/3191) This article is protected by copyright. All rights reserved.
Accepted Article in our cohort. Germline mutations in MLH1, MSH2, MSH6, PMS2, and EPCAM accounted for 42.4%, 36.4%, 15.2%, 5.1%, and 1.0% of all mutations, respectively.
One third (33/99) of the mutations have not been reported previously. The c.793C>T missense mutation in MLH1 (7 patients) and c.1452_1455 deletion mutation in MSH2 (6 patients) were the two most common mutations. Overall, we found 35 frameshift mutations, 25 nonsense mutations, 14 missense mutations, 14 CNVs, 10 splice site mutations and 1 in-frameshift mutation. Frameshift mutations were the most common type found in MLH1, MSH2 and MSH6, while pathogenic missense mutations were common in MLH1 (eFigure in the Supplement).
There were 70 variants of uncertain significance (VUS) in MMR genes that were detected in 57 patients. Missense mutations were the most common type and accounted for 64.3% of the VUS. Twenty-seven (60%) of the missense mutations were consistent with IHC results, showing loss of the protein product of the mutant gene (eTable 2 in the Supplement). Four variants fulfilled criteria for upgrading to likely pathogenic. Given that the conserved functional domain without benign variation was established based on an in-house database, we classified these 4 patients as highly suspicious for having LS and therefore, close clinical follow up was recommended.
Strategies for Screening
Clinical strategies for LS screening were also evaluated ( Table 2 ). Only 9 (9.7%) patients with LS fulfilled Amsterdam criteria II. In addition, using the revised Bethesda guidelines as a prescreening method would have left 17 (18.3%) cases undiagnosed. Although the universal tumor screening strategy provides the greatest sensitivity, its positive predictive value was relatively low at 36.3%.We also evaluated the relationship between age of onset and prevalence of LS in patients with dMMR 
Discussion
Previous studies have shown that universal screening of all CRC cases for LS by analysis of microsatellite instability or IHC for MMR proteins is the most sensitive 15 and probably most cost-effective strategy. [16] [17] [18] However, its application in Chinese population has not been well investigated, especially in a large unselected CRC series. This article is protected by copyright. All rights reserved.
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Furthermore, there were 376,300 new diagnoses of CRC in 2015 in China 19 , nearly one fourth of the new cases worldwide. Although our patients were mainly from southern China, the results still could be a great supplementary to the ethnic diversity of LS and fundamental data for direct implications on clinical practice.
In our study, 330 (10.2%) patients were found to have tumors with dMMR and 93 (2.9%) were diagnosed as LS. Considering that 59 (18.7%) patients with dMMR and no BRAF V600E mutation did not receive germline sequencing, and the possibility of undiagnosed LS cases with constitutional MLH1 promoter methylation 20 , the incidence of LS is expected to be higher than 2.9% in our population. This result was similar to that found in Finnish and American studies 3, 21 , and much higher than reported in Mediterranean or Japanese populations where the prevalence was no more than 1%. 22, 23 However, the overall incidence of dMMR CRCs found in Chinese patients was relatively low compared with western populations. In a population-based study from the Ohio metropolitan area of the United States, the incidence of dMMR was as high as 14%-16%. 3, 24 These differences might be explained by the variation in epigenetic background among populations. It is well known that sporadic CRCs exhibit dMMR because of somatic inactivation of the MLH1 gene by promoter methylation in tumours arising along the sessile serrated pathway. 25 In western population, the proportion of MLH1 absence was 70%-80% of all dMMR tumors, 22, 26 while it accounted for only 47.9% in our Chinese cohort. Importantly, the prevalence of BRAF V600E mutation is much higher in CRC tumors with absence of MLH1 in western countries than we found in our study population (9.9%). This is probably a function of the younger age of CRC diagnosis in this Chinese cohort, as somatic MLH1 methylation is much more common in older patients. 27 BRAF V600E mutation analysis has been reported to be a valid tool to exclude LS because this mutation is generally absent in patients with LS and is associated with promoter hypermethylation of MLH1 gene in sporadic CRCs. 28 It is recommended to test for the BRAF V600E mutation in colorectal tumors with absence of MLH1 protein expression before proceeding to germline sequencing. 29 In a population-based screening program for LS in Australia, 154 (75%) BRAF V600E mutations were detected in 205 patients with lack of MLH1 protein expression. 26 Recent studies have revealed that BRAF V600E mutation analysis has a low negative predictive value for MLH1 promoter methylation, especially in patients aged more than 70 years. 30 Using BRAF genotyping alone as a prescreening test would increase referral rates for genetic testing over 2-fold compared with MLH1 methylation testing. Given the low incidence of BRAF V600E mutation in our cohort, the test seems less efficient in reducing the number of patients who require germline MMR gene sequencing. Based upon our study results, we therefore suggest that Chinese patients with absence of MLH1 on IHC should go directly to germline testing rather than using BRAF V600E testing for prescreening.
Another strength of this study lies in the fact that we evaluated the relationship between the age of onset and prevalence of LS in patients with dMMR tumors. Given that determination of tumor MMR status has advantages in assessing prognosis and directing adjuvant chemotherapy or immunotherapy as well [31] [32] [33] , MMR or MSI testing is suggested in all patients with CRC nowadays. 34, 35 Although universal tumor screening provides the highest sensitivity, the low positive predictive value limited its application in large population. We had to balance both sensitivity and positive rate, so that the screening strategy could be more cost-effective. According to our cohort, most patients with LS developed CRC in their 40s or 50s, so the prevalence of LS is very low (2/35, 5.7%) in CRC patients older than 65 years even with dMMR tumors.
In this case, universal sequencing for patients with dMMR tumor might not be necessary, and selective sequencing of cases with dMMR and older than 65 years fulfilling the revised Bethesda guidelines result in 8.2% fewer cases requiring germline testing without missing any LS diagnoses. Since germline tests are time consuming and costly, the selective strategy is effective and could be an alternative approach for LS screening.
Interestingly, two common mutations were detected in our cohort. The c.793C>T missense mutation accounted for 16.7% (7/42) of all pathogenic MLH1 mutation cases and the c.1452_1455 deletion responsible for 16.7% (6/36) of MSH2 mutation cases identified. Both of these mutations have been reported previously. The former was detected in Taiwanese LS families 36 while the latter was found in Hong Kong Chinese. 37 Since there were major emigrations in China during the last several centuries, these two mutations are deemed as founder mutations inthe southern Chinese population. Considering that we still have several novel mutations identified in at least two ostensibly unrelated patients, the possibility of additional founder mutations existsand further study is required.
Naturally, this study has limitations. First, direct assay for MLH1 promoter methylation was not performed, such that the incidence of epigenetic gene inactivation as a cause of dMMR and LS in Chinese CRC patients was unknown.
However, the proportion of LS patients with constitutional MLH1 promoter methylation in other populations is only approximately 1%. 20 So this is unlikely to be a large effect in our results. Furthermore, we could not address whether direct methylation testing is a feasible approach for enriching suspected patients for further sequencing than BRAF testing. The selective strategy derived from our cohort awaits confirmation in another cohort of patients with CRC. Additional studies will be indispensable to determine its cost-effectiveness. Lastly, further studies of the MMR genes with variants of uncertain significance, such as segregation of mutations, functional assays, and somatic sequencing, are important to clarify the pathogenicity of these mutations and guide future surveillance for these families, which will be facilitated by the InSiGHT MMR LOVD and Variant Interpretation Committee, now recognized as the ClinVar Expert Panel for MMR genes. 38 To our knowledge, this is one of the most comprehensive studies for LS in CRC This article is protected by copyright. All rights reserved.
patients. Although the incidence of LS is similar to that of western population, the spectrum of mutations and frequency of sporadic dMMR indicated by MLH1 loss and concurrent BRAF V600E mutation is quite different, supporting that LS do has ethnic diversity. The age of onset indicates risk of LS in CRC patients with dMMR tumors.
Selective germline sequencing in patients with dMMR tumors diagnosed at age 65 years or younger, and in older patients fulfilling the revised Bethesda guidelines is optimal and could be an alternative approach to universal tumor screening for LS. 
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